Orforglipron vs Semaglutide: What the Research Shows
Orforglipron and Semaglutide side by side: what they are, how they are regulated and what is still unknown.
Where the research points
Consider Orforglipron if…
- you want an FDA-approved oral option: Foundayo (orforglipron) is labelled, with diet and activity, to reduce excess body weight in adults with obesity or with overweight plus a weight-related condition[6]
- you want an oral option with randomized weight-loss data: Body weight changed by -7.5% (6 mg), -8.4% (12 mg) and -11.2% (36 mg) with orforglipron vs -2.1% with placebo at week 72.[16]
Consider Semaglutide if…
- you want an FDA-approved product: Wegovy (semaglutide) is labelled to reduce excess body weight and maintain weight reduction long term in adults with obesity, or with overweight plus a weight-related condition[15]
- you want cardiovascular-outcomes data in obesity without diabetes: The primary cardiovascular composite occurred in 6.5% on semaglutide vs 8.0% on placebo (hazard ratio 0.80, 95% CI 0.72 to 0.90).[18]
What they have in common
- In the ACHIEVE-3 head-to-head trial, HbA1c changed by -1·91% with orforglipron 36 mg vs -1·47% with semaglutide 14 mg at week 52[8]
Spec comparison
Showing 7 of 11 fields where the two differ. Category, PCAC vote, Jul 2026, WADA, Evidence strength are the same or both unknown.
| Field | Orforglipron | Semaglutide |
|---|---|---|
| Class | Oral small-molecule GLP-1 agonist | GLP-1 agonist |
| Also called | Foundayo, orfo | sema, Ozempic, Wegovy, Rybelsus, Wegovy pill |
| Category | GLP-1 & metabolic | GLP-1 & metabolic |
| FDA status | FDA approved (Foundayo, Apr 2026) | FDA approved (Ozempic, Wegovy, Rybelsus) |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | Not on the Jul 2026 agenda |
| WADA | Not on the WADA Prohibited ListGLP-1 and GIP agonists are not named anywhere on the 2026 list. This one is an approved medicine, so the catch-all S0 (which only covers drugs with no approval anywhere) does not apply to it. | Not on the WADA Prohibited ListGLP-1 and GIP agonists are not named anywhere on the 2026 list. This one is an approved medicine, so the catch-all S0 (which only covers drugs with no approval anywhere) does not apply to it. |
| Half-life | approximately 29 to 49 hoursoral · FDA label (Foundayo) | approximately 1 weeksubcutaneous · FDA label (Ozempic) |
| Evidence strength | Human RCT evidence, 4 of 4Strongest: Lancet 2026, PMID 41275875 | Human RCT evidence, 4 of 4Strongest: Lancet 2026, PMID 41865758 |
| Human studies we summarised | 14 human (13 randomized or controlled) of 15 summarised | 23 human (19 randomized or controlled) of 27 summarised |
| Typical study doses |
|
|
| Named in FDA warning letters, 2026 | Not in the letters we track | Yes (24 Aug 2026; 31 Mar 2026) |
Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.
The head-to-head is in diabetes, against oral semaglutide
The direct comparison is ACHIEVE-3, in adults with type 2 diabetes inadequately controlled on metformin, comparing orforglipron with oral semaglutide.[8]
In ACHIEVE-3, both orforglipron doses showed superiority to both oral semaglutide doses, including orforglipron 12 mg versus semaglutide 14 mg.[8]
Gastrointestinal events were the most frequent adverse events: 59% on orforglipron 12 mg and 58% on 36 mg, against 37% on semaglutide 7 mg and 45% on 14 mg.[8]
Mean pulse rate rose by 3.7 bpm on orforglipron 12 mg and 4.7 bpm on 36 mg, a greater increase than in the semaglutide groups.[8]
No direct orforglipron versus Wegovy comparison is in the cache. The Wegovy pivotal trial reported a mean body weight change to week 68 of -14.9% on semaglutide against -2.4% on placebo.[17]
Dosing and label differences
The Wegovy tablet label says to wait at least 30 minutes after taking it before eating, drinking beverages or taking other oral medications.[15]
The Wegovy tablet label says to initiate it at 1.5 mg once daily for 30 days.[15]
Foundayo is a once-daily oral product, and its label allows dosing with or without food.[6]
In cohort 2 of the ATTAIN-MAINTAIN trial, participants who reached a body weight plateau maintained 79.3% of their weight reduction on orforglipron, against 37.6% on placebo.[19]
Common questions
Is orforglipron better than Rybelsus?
In the diabetes head-to-head against oral semaglutide, orforglipron showed superiority on efficacy, and gastrointestinal events were more frequent on it.[8]
Orforglipron vs Wegovy: which works better for weight loss?
No study compares them head to head in obesity; each beat placebo in its own trial.[16]
Can you take orforglipron after stopping semaglutide?
The cached maintenance trial randomized participants to orforglipron or placebo after prior weight loss; in cohort 2, those who reached a plateau kept 79.3% of the reduction on orforglipron versus 37.6% on placebo.[19]
Sources
- 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
- 2FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks listFDA · 2026fda.govAccessed 2 Oct 2026
- 3Orforglipron approved as FoundayoFDA · 2026fda.govAccessed 2 Oct 2026
- 4Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
- 5World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 6These highlights do not include all the information needed to use FOUNDAYO safely and effectively. See full prescribing information for FOUNDAYO. FOUNDAYO (orforglipron) tablets, for oral use Initial FDA label (Foundayo), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 7Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.Lancet (London, England) · 2026PMID 41275875Accessed 2 Oct 2026
- 8Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial.Lancet (London, England) · 2026PMID 41765029Accessed 2 Oct 2026
- 9Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial.Lancet (London, England) · 2026PMID 42259339Accessed 2 Oct 2026
- 10These highlights do not include all the information needed to use OZEMPIC ® safely and effectively. See full prescribing information for OZEMPIC. OZEMPIC (semaglutide) injection, for subcutaneous use FDA label (Ozempic), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 11Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials.Lancet (London, England) · 2026PMID 41865758Accessed 2 Oct 2026
- 12Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.The New England journal of medicine · 2025PMID 40305708Accessed 2 Oct 2026
- 13Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity.The New England journal of medicine · 2025PMID 40934115Accessed 2 Oct 2026
- 14PubMed search: (orforglipron[tiab] OR LY3502970[tiab] OR Foundayo[tiab]) AND (semaglutide[tiab] OR Ozempic[tiab] OR Wegovy[tiab] OR Rybelsus[tiab] OR NN9535[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 15WEGOVY prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 16Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.The New England journal of medicine · 2025PMID 40960239Accessed 2 Oct 2026
- 17Once-Weekly Semaglutide in Adults with Overweight or Obesity.The New England journal of medicine · 2021PMID 33567185Accessed 2 Oct 2026
- 18Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.The New England journal of medicine · 2023PMID 37952131Accessed 2 Oct 2026
- 19Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial.Nature medicine · 2026PMID 42120723Accessed 2 Oct 2026
Found an error? Report a correction.